1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: A promising class of monoamine uptake inhibitors

Journal of Medicinal Chemistry

Volumn 49, Issue 4, 2006, Pages 1420-1432

  Meltzer, Peter C ^a   Butler, David ^a   Deschamps, Jeffrey R ^b   Madras, Bertha K ^c  

^a ORGANIX INC   (United States)

^b NAVAL RESEARCH LABORATORY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4 DICHLOROPHENYL) 2 PYRROLIDIN 1 YLPENTAN 1 ONE; 1 NAPHTHALEN 2 YL 2 PYRROLIDIN 1 YLPENTAN 1 ONE; COCAINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE UPTAKE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PYROVALERONE; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1C RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; COCAINE DEPENDENCE; DOPAMINERGIC TRANSMISSION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; EVALUATION; HUMAN; HUMAN CELL; ISOMER; NEUROTRANSMISSION; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; RECEPTOR AFFINITY; STRUCTURE ANALYSIS;

ADRENERGIC UPTAKE INHIBITORS; BINDING, COMPETITIVE; CELL LINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; HUMANS; LIGANDS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PENTANONES; PYRROLIDINES; RADIOLIGAND ASSAY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33144477907     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050797a     Document Type: Article

References (48)

1. Schildkraut, J. J. The catecholamine hypothesis of affective disorders: A review of supporting evidence. J. Psychiatry 1965, 122, 509-522.
2. Madras, B. K.; Pristupa, Z. B.; Niznik, H. B.; Liang, A. Y.; Blundell, P.; Gonzalez, M. D.; Meltzer, P. C. Nitrogen-based drugs are not essential for blockade of monoamine transporters. Synapse 1996, 24, 340-348.
3. Biederman, J.; Spencer, T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol. Psychiatry 1999, 46, 1234-1242.
4. Popper, C. W. Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc. Psychiatr. Clin. N Am. 2000, 9, 605-646.
5. Fleckenstein, A. E.; Gibb, J. W.; Hanson, G. R. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur. J. Pharmacol. 2000, 406, 1-13.
6. Gorelick, D. A.; Gardner, E. L.; Xi, Z. X. Agents in development for the management of cocaine abuse. Drugs 2004, 64, 1547-1573.
7. Gainetdinov, R. R.; Caron, M. G. Monoamine transporters: From genes to behavior. Annu. Rev. Pharmacol. Toxicol. 2002, 43, 261-284.
8. Vocci, F. J.; Acri, J.; Elkashef, A. Medications development for addictive disorders: the state of the science. Am. J. Psychiatry 2005, 762, 1432-1440.
9. Coyle, J. T.; Snyder, S. H. Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science 1969, 166, 899.
10. Iversen, L. L. Uptake Process of Bio genie Amines; Plenum: New York, 1975; pp 381-442.
11. Meltzer, P. C.; Blundell, P.; Madras, B. K. Structure activity relationships of inhibition of the dopamine transporter by 3-arylbicyclo[3.2.1] octanes. Med. Chem. Res. 1998, 8, 12-34.
12. Meltzer, P. C.; Wang, B.; Chen, Z.; Blundell, P.; Jayaraman, M.; Gonzalez, M. D.; George, C.; Madras, B. K. Synthesis of 6- and 7-hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters. J. Med. Chem. 2001, 44, 2619-2635.
13. Meltzer, P. C.; Liu, S.; Blanchette, H. S.; Blundell, P.; Madras, B. K. Design and synthesis of an irreversible dopamine-sparing cocaine antagonist. Bioorg. Med. Chem. 2002, 10, 3583-3591.
14. Madras, B. K.; Fahey, M. A.; Miller, G. M.; De La Garza, R.; Goulet, M.; Spealman, R. D.; Meltzer, P. C.; George, S. R.; O'Dowd, B. F.; Bonab, E.; Livni, E.; Fischman, A. J. Non-amine-based dopamine transporter (reuptake) inhibitors retain properties of amine-based progenitors. Eur. J. Pharmacol. 2003, 479, 41-51.
15. Kennedy, L. T.; Hanbauer, I. Sodium sensitive cocaine binding to rat striatal membrane: possible relationship to dopamine uptake sites. J. Neurochem. 1983, 34, 1137-1144.
16. 3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinson's disease. Naunyn-Schmiedeberg's Arch. Pharmacol. 1985, 529, 227-235.
17. Reith, M. E. A.; Meisler, B. E.; Sershen, H.; Lajtha, A. Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem. Pharmacol. 1986, 35, 1123-1129.
18. Ritz, M. C.; Lamb, R. J.; Goldberg, S. R.; Kuhar, M. J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987, 257, 1219-1223.
19. 3H]Cocaine binding sites in caudate-putamen. J. Pharmacol. Exp. Ther. 1989, 251, 131-141.
20. Bergman, J.; Madras, B. K.; Johnson, S. E.; Spealman, R. D. Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J. Pharmacol. Exp. Ther. 1989, 251, 150-155.
21. 3H]WIN 35,428) in the monkey brain. Synapse 1990, 6, 189-195.
22. 3H]-cocaine receptors. Pharmacol., Biochem. Behav. 1990, 35, 949-953.
23. Kaufman, M. J.; Madras, B. K. Severe depiction of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse 1991, 9, 43-49.
24. Kuhar, M. J.; Ritz, M. C.; Boja, J. W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. 1991, 14, 299-302.
25. Servin, A.; Jacquot, C. N.; Rapin, J. R. Effects of pyrovalerone on peripheral noradrenergic mechanisms. Biochem. Pharmacol. 1978, 27, 1693-1694.
26. Perrine, D. M.; Ross, J. T.; Nervi, S. J.; Zimmerman, R. H. A short, one-pot synthesis of bupropion. J. Chem. Educ. 2000, 77, 1479-1480.
27. Musso, D. L.; Mehta, N. B.; Soroko, F. E.; Ferris, R. M.; Hollingsworth, E. B.; Kenney, B. T. Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion. Chiralitv 1993, 5, 495-500.
28. Lancelot, J. C.; Robba, M.; Bonnet, J. J.; Vaugeois, J. M.; Costentin, J. Synthesis and preliminary study of the activity of thiophene analogues of pyrovalerone on the neuronal uptake of the monoamines. Eur. J. Med. Chem. 1992, 27, 297-300.
29. Heffe, W. Die Stevens-umlagerung von allyl-phenacyl-ammoniumsalzen. Helv. Chim. Acta 1964, 47, 1289-1292.
30. Stille, G.; Ackermann, H.; Eichenberger, E.; Lauener, H. Vergleichende pharmakologische untersuching eines sentralem Stimulans 1-p-tolyl-1-oxo-2- pyrrolidino-n-pentan-HCl. Arzneim.-Forsch. 1963, 13, 871-877.
31. Holliday, A. R.; Morris, R. B.; Sharpley, R. P. Compound 84/F 1983 compared with D-amphetamine and placebo in regard to effects on human performance. Psychopharmacologia 1964, 6, 192-200.
32. Gardos, G.; Cole, J. O. Evaluation of pyrovalerone in chronically fatigued volunteers. Curr. Ther. Res. 1971, 13, 631-635.
33. Fauquet, J.-P.; Morel, E.; Demarty, C.; Rapin, J. R. Role des catecholamines centrales dans l'activite psychostimulante de la pyrovalerone. Arch. Int. Pharmacodyn. Ther. 1976, 224, 325-337.
34. Vaugeois, J.-M.; Bonnet, J.-J.; Duterte-Boucher, D.; Costentin, J. In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion. Eur. J. Pharmacol 1993, 230, 195-201.
35. Michaelis, W.; Russel, J. H.; Schindler, O. The metabolism of pyrovalerone hydrochloride. J. Med. Chem. 1970, 13, 497-503.
36. Eshleman, A. J.; Carmolli, M.; Cumbay, M.; Martens, C. R.; Neve, K. A.; Janowsky, A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J. Pharmacol. Exp. Ther. 1999, 289, 877-885.
37. 3H]cocaine in striatum and its relationship to the dopamine transporter. Membr. Biochem. 1987, 7, 87-106.
38. Glennon, R. A.; Young, R.; Martin, B. R.; Dal Cason, T. A. Methcathione ("cat"): an enantiomeric potency comparison. Pharmacol., Biochem. Behav. 1995, 50, 601-606.
39. Carroll, F. I.; Gao, Y.; Rahman, M. A.; Abraham, P.; Parham, K.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. Synthesis, ligand binding, QSAR, and CoMFA study of 3β-(p-substituted phenyl)tropane-2β-carboxylic acid methyl esters. J. Med. Chem. 1991, 34, 2719-2725.
40. Newman, A. H.; Izenwasser, S.; Robarge, M. J.; Kline, R. H. CoMFA study of novel phenyl ring-substituted 3α-(diphenylmethoxy)tropane analogues at the dopamine transporter. J. Med. Chem 1999, 42, 3502-3350.
41. Deutsch, H. M. Structure-activity relationships for methylphenidate analogs and comparisons to cocaine and tropanes. Med. Chem. Res. 1998, 8, 91-99.
42. Meltzer, P. C.; Wang, P.; Blundell, P.; Madras, B. K. Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate. J. Med. Chem. 2003, 46, 1538-1545.
43. Newman, A. H. Novel dopamine transporter ligands: The state of the art. Med. Chem. Res. 1998, 8, 1-11.
44. Carroll, F. I.; Howell, L. L.; Kuhar, M. J. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J. Med. Chem. 1999, 42, 2721-2736.
45. Carroll, F. I. 2002 Medicinal chemsitry division award address: monoamine transporters and opioid receptors. Targets for addiction therapy. J. Med. Chem. 2003, 46, 1775-1794.
46. Deutsch, H. M.; Collard, D. M.; Zhang, L.; Burnham, K. S.; Deshpande, A. K.; Holtzman, S. G.; Schweri, M. M. Synthesis and pharmacology of site-specific cocaine abuse treatment agents: 2-(aminomethyl)-3-phenylbicyclo[2.2.2]- and -[2.2.1]alkane dopamine uptake inhibitors. J Med. Chem. 1999, 42, 882-895.
47. Carroll, F. I.; Pawlush, N.; Kuhar, M. J.; Pollard, G. T.; Howard, J. L. Synthesis, monoamine transporter binding properties, and behavioral pharmacology of a series of 3β-(substituted phenyl)-2β-(3′-substituted isoxazol-5-yl)tropanes. J. Med. Chem. 2004, 47, 296-302.
48. Meltzer, P. C.; Madras, B. K. Unpublished data.